Ferritin is the primary intracellular iron storage protein, and serum ferritin is the best single marker of whole-body iron stores. Low ferritin is diagnostic of iron deficiency before anemia develops and reflects the most common nutritional deficiency worldwide. However, ferritin is also an acute-phase reactant — it rises with inflammation, infection, malignancy, liver disease, and metabolic syndrome — which can mask iron deficiency and complicate interpretation without inflammatory context.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Worried about fatigue, poor energy, sluggish cognition, or hair loss — or concerned about iron overload if you have a family history of hemochromatosis? Ferritin testing reveals what your body's iron stores actually are, independent of recent meals or acute stress. Iron deficiency is silent and widespread; it can blunt energy, cognition, and thyroid function long before you become anemic. Equally, iron excess is common and dangerous, especially in Northern European populations where the HFE mutation (hereditary hemochromatosis) is prevalent — including Sweden — and raises lifetime risk of liver disease, diabetes, and heart disease.
A single ferritin measurement, interpreted in context of inflammation (hs-CRP), tells you whether you need urgent iron repletion, monitoring, or phlebotomy.
Detects iron deficiency early. Ferritin is the first marker to fall when iron stores deplete, catching deficiency before anemia develops and symptoms become severe.
Clarifies fatigue and cognitive complaints. Low iron impairs mitochondrial function, oxygen transport, and thyroid hormone synthesis, making ferritin testing crucial when energy or focus is unexpectedly poor.
Flags hereditary hemochromatosis and iron overload. Elevated ferritin signals need for further workup (HFE genotyping, transferrin saturation, liver imaging) — critical in Scandinavian populations where this genetic condition is common.
Contextualizes inflammation. When paired with hs-CRP, ferritin reveals whether elevation is due to iron burden or inflammatory-state artifact — essential for correct interpretation.
Guides thyroid function interpretation. Iron is a cofactor for thyroid peroxidase; low ferritin can impair thyroid hormone synthesis and complicate TSH interpretation.
Tracks metabolic syndrome and liver health. Elevated ferritin clusters with insulin resistance, non-alcoholic fatty liver disease (MASLD), and visceral adiposity — signaling cardiometabolic risk.
Iron storage and bodily iron economy. Ferritin is a protein shell that sequesters iron inside cells, protecting tissues from iron's pro-oxidant toxicity while making iron available for heme synthesis and mitochondrial respiration. The body has no active iron-excretion pathway — iron is shed only through bleeding, skin shedding, and gut loss. When iron intake exceeds loss, iron accumulates inside cells, bound to ferritin. When intake is insufficient, ferritin releases iron to maintain circulating iron (transferrin-bound iron) for hemoglobin and enzyme synthesis. Serum ferritin — the small amount of ferritin that leaks from cells into blood — directly mirrors intracellular iron stores.
The acute-phase reactant problem. Ferritin is also a pro-inflammatory cytokine-responsive protein. Cytokines like TNF-α and IL-6 (released during infection, autoimmunity, malignancy, liver disease, severe obesity, and metabolic syndrome) drive hepatic ferritin synthesis independent of iron status. This means a patient with true iron deficiency can show a “normal” or even elevated ferritin if they are simultaneously inflamed — the inflammation masks the deficiency. Conversely, isolated ferritin elevation in the absence of true iron overload is often inflammatory in origin. This is why hs-CRP (high-sensitivity C-reactive protein) context is mandatory: low ferritin + low hs-CRP = true iron deficiency; high ferritin + high hs-CRP = inflammation (and possibly masked iron deficiency if ferritin is only modestly elevated); high ferritin + low hs-CRP = true iron burden.
Identifies hidden metabolic dysfunction. Elevated ferritin independently predicts type 2 diabetes, cardiovascular events, and all-cause mortality in prospective cohorts — even after controlling for inflammation. Iron excess drives insulin resistance via hepatic oxidative stress and mitochondrial dysfunction.
Catches iron deficiency before anemia. WHO defines iron deficiency as ferritin < 30 µg/L, and functional iron deficiency (depleted stores but still normal hemoglobin) as ferritin < 100 µg/L with elevated hs-CRP. By the time hemoglobin falls, cognitive and mitochondrial damage is often underway.
Flags hemochromatosis in high-risk populations. HFE mutations are carried by 1 in 200–300 individuals in Northern Europe, with higher frequency in Sweden. Undiagnosed hemochromatosis progresses silently to cirrhosis, hepatocellular carcinoma, diabetes, and heart disease over decades — early detection via ferritin and HFE genotyping is life-altering.
Quantifies iron-driven inflammation. When interpreted with hs-CRP and transferrin saturation, ferritin reveals whether you are iron-loaded (requiring phlebotomy), iron-deficient (requiring repletion), or acutely inflamed (requiring anti-inflammatory intervention).
WHO iron deficiency threshold: < 30 µg/L signals iron deficiency; < 15 µg/L confirms depletion.
Functional iron deficiency (with inflammation): < 100 µg/L when hs-CRP is elevated (> 1.0 mg/L).
Standard Swedish healthcare “normal” range (vårdcentralen): 30–300 µg/L (male and postmenopausal female); 15–200 µg/L (menstruating female). This is a wide range and reflects population-level variation, not optimization.
Loovi optimal (longevity and energy): 50–150 µg/L. This range supports mitochondrial function, thyroid hormone synthesis, cognitive reserve, and is well below the threshold for iron-driven metabolic risk.
Hemochromatosis workup threshold: > 300 µg/L, or any ferritin > 200 µg/L with low hs-CRP (true iron burden rather than inflammation). Warrants HFE genotyping, transferrin saturation measurement, and liver imaging.
Risk begins to rise above 200 µg/L, especially if hs-CRP is low (indicating true iron excess rather than inflammatory artifact). The delta between Standard and Loovi Optimal reflects the shift from reactive (waiting for pathology) to proactive (maintaining mitochondrial reserve).
Low ferritin (< 30 µg/L). You have depleted iron stores. If hs-CRP is also low (< 1.0 mg/L), this is genuine iron deficiency and merits investigation for cause (blood loss, malabsorption, inadequate intake, heavy menstruation, endurance training). You may not yet be anemic — hemoglobin can be normal while ferritin-bound iron is exhausted — but you are likely experiencing fatigue, poor cognition, and impaired thyroid function. Low ferritin also associates with restless-leg syndrome and hair loss.
Optimal ferritin (50–150 µg/L). Your iron stores are adequate for energy, mitochondrial function, and thyroid synthesis. This range supports cognitive reserve and metabolic flexibility. Your transferrin saturation should be normal (< 45%); if it is elevated despite ferritin in this range, it signals acute iron absorption (recent high iron meal or supplementation) rather than pathology.
High ferritin (150–300 µg/L). Investigate context. If hs-CRP is > 1.0 mg/L, the elevation is largely inflammatory, driven by cytokines from adiposity, metabolic endotoxemia, or subclinical infection. Address the inflammation (sleep, training, nutrition, stress) rather than iron-restriction. If hs-CRP is low but ferritin is persistently > 200 µg/L, you have true iron excess and warrant HFE genotyping and transferrin saturation measurement to rule out hereditary hemochromatosis or secondary iron overload (alcoholic liver disease, hemolytic anemia, repeated transfusion).
Very high ferritin (> 300–400 µg/L). This always warrants urgent investigation, regardless of hs-CRP. Causes include hereditary hemochromatosis (especially in Swedish and Northern European ancestry), alcoholic or non-alcoholic liver disease (MASLD), hematologic malignancy, chronic hemolysis, and iron overload from transfusion. Transferrin saturation > 45%, abnormal liver enzymes (ALT, GGT), or HFE homozygosity would support hemochromatosis; elevated ALT alone suggests MASLD. Liver ultrasound or transient elastography may be needed to assess fibrosis.
Factors that influence ferritin. Menstruation and heavy bleeding lower ferritin; pregnancy raises it slightly (though stores may be depleted). Intense endurance exercise within 48 hours can mildly elevate ferritin. Recent high-dose iron supplementation or transfusion raises it acutely. Acute infection, recent vaccination, trauma, or surgery raises it temporarily via IL-6 and TNF-α. Chronic liver disease, malignancy, and metabolic syndrome chronically elevate it. Alcohol consumption raises ferritin and impairs iron metabolism. Some medications (estrogen-containing contraceptives can worsen iron absorption in deficient individuals).
Genetics and hereditary hemochromatosis. HFE mutations (C282Y homozygosity most common, H63D heterozygosity less penetrant) impair hepcidin regulation, causing iron to accumulate in liver, heart, and pancreas. Prevalence is 1 in 200–300 in Northern Europe; Sweden has a high carrier frequency. Most homozygotes never develop symptomatic disease if caught early by ferritin screening and HFE genotyping.
Dietary iron intake and absorption. Vegetarian or restrictive diets low in heme iron (red meat, fish) drive deficiency if intake is insufficient. Conversely, excessive red meat or iron supplementation in genetically-predisposed individuals accelerates hemochromatosis. Malabsorption (celiac disease, inflammatory bowel disease, gastric bypass) impairs iron absorption despite adequate intake.
Metabolic dysfunction and insulin resistance. Elevated ferritin clusters tightly with insulin resistance, visceral adiposity, and non-alcoholic fatty liver disease (MASLD). The mechanism is bidirectional: insulin resistance increases hepcidin, raising iron absorption; elevated intracellular iron drives hepatic oxidative stress and worsens insulin resistance. This makes ferritin a marker of cardiometabolic risk independent of inflammation.
Age, sex, and blood loss. Menstruating women have lower ferritin than men and postmenopausal women (a natural protective factor). Heavy menstrual bleeding, chronic GI bleeding (ulcers, polyps, malignancy), or recurrent blood donation rapidly deplete stores. Men have no physiologic iron loss, so ferritin naturally rises with age unless offset by dietary restraint or phlebotomy.
Chronic inflammation, infection, and malignancy. Acute-phase cytokines (IL-6, TNF-α) induced by infection, autoimmunity (rheumatoid arthritis, lupus), chronic kidney disease, cancer, and severe obesity drive ferritin synthesis. This is a confounding variable — high ferritin can represent inflammation rather than iron burden, emphasizing the need for hs-CRP context.
Iron repletion (for deficiency). Low ferritin responds to increasing heme iron intake (red meat, fish, shellfish — the most bioavailable form) or supplemental iron, which must be dosed carefully to avoid overdose and oxidative stress. Oral iron (ferrous sulfate, glycinate, or bisglycinate) is absorbed passively in the proximal small intestine and competes with other divalent cations. Vitamin C enhances absorption; calcium, tea, and coffee inhibit it. The liver tightly regulates hepcidin in response to iron stores and inflammation, so repletion is self-limiting — once ferritin normalizes, further iron absorption is suppressed. Parenteral iron (intravenous infusions) bypasses absorption and is reserved for severe deficiency or malabsorption.
Iron restriction (for overload). Elevated ferritin without inflammatory markers demands dietary iron minimization — limiting red meat, shellfish (especially oysters), and iron-fortified foods — and investigating underlying cause (HFE genotyping, transferrin saturation, liver imaging). Phlebotomy (venesection) is the gold standard for hereditary hemochromatosis and removes one unit of blood (500 mL, roughly 250 mg iron) at a time. The frequency of phlebotomy is titrated to ferritin targets and HFE status. Chelation (deferoxamine, deferasirox) is reserved for transfusion-dependent anemia or severely overloaded patients who cannot tolerate phlebotomy.
Inflammation management (for masked or concurrent iron deficiency with high hs-CRP). If ferritin is elevated because inflammation is elevated, addressing the underlying drivers — sleep quality, recovery from training stress, dietary endotoxins, gut dysbiosis, visceral adiposity — reduces both cytokine production and ferritin synthesis. This can unmask true iron deficiency if it exists beneath the inflammatory layer. Conversely, anti-inflammatory pharmacology (low-dose colchicine, certain statins) can lower ferritin slightly, though this is rarely a primary target.
The right intervention depends on your ferritin, hs-CRP, transferrin saturation, HFE genotype, and full cardiometabolic profile — this is what a Loovi longevity doctor will map out in consultation, not a protocol to follow independently.
Ferritin in a vacuum is clinically half-blind. You must know the inflammatory context (hs-CRP) to distinguish true iron deficiency from inflammatory artifact. You should know transferrin saturation — the percentage of transferrin occupied by iron — to confirm whether ferritin elevation reflects iron burden or transient absorption. You need to know hemoglobin and mean corpuscular volume (MCV) to assess whether iron deficiency has progressed to anemia or whether you are iron-overloaded with normal blood counts. You should measure thyroid function (TSH, fT4) because iron deficiency impairs thyroid peroxidase and can worsen hypothyroidism. And in individuals with high ferritin, you want liver enzymes (ALT, GGT) and HFE genotyping to rule out hemochromatosis, especially if you have Swedish or Northern European ancestry.
Loovi's membership tracks all of these biomarkers together — 120+ annually — alongside physical tests (VO2 max, strength, mobility) and unrushed longevity doctor consultations that weave ferritin into your full metabolic story. That's how you move from isolated lab curiosity to actionable biological insight.
Ferritin-replete individuals can still be fatigued from poor sleep, inadequate training recovery, vitamin B12 deficiency, thyroid dysfunction, or undiagnosed inflammation (hs-CRP can reveal this). Iron is necessary but not sufficient for energy. If ferritin is > 50 µg/L and hs-CRP is low, iron deficiency is unlikely; investigate other causes with your doctor.
Yes — this is the core nuance. Elevated ferritin with elevated hs-CRP (> 1 mg/L) usually reflects inflammation, not iron excess. Infection, obesity, autoimmunity, liver disease, and metabolic syndrome all drive ferritin up via cytokines. If hs-CRP is high but ferritin is < 100 µg/L, true iron stores may actually be low (masked by inflammation). Lowering hs-CRP through sleep, training, and metabolic optimization can lower ferritin and unmask any underlying iron deficiency.
Intense endurance exercise (especially running) can mildly elevate ferritin for 24–48 hours post-workout via acute-phase response. Recent vaccination or acute infection triggers IL-6 and TNF-α, raising ferritin temporarily. If you tested within 3 days of intense training or vaccination, retest 1–2 weeks later. Chronically elevated ferritin (stable across multiple tests) reflects iron burden, metabolic dysfunction, or chronic inflammation, not transient exercise response.
This pattern is unusual and suggests acute iron absorption (high iron meal or recent supplementation) in an otherwise iron-deficient state. Transferrin saturation naturally rises when you consume iron-rich food because iron floods into circulation before your liver adjusts hepcidin. Retest ferritin and transferrin saturation in a fasted state a few days after controlling iron intake; chronically elevated transferrin saturation (> 45%) with normal ferritin warrants HFE genotyping.
Yes — HFE mutations, especially C282Y homozygosity, are more common in Nordic countries than in most of the world, reflecting Scandinavian genetic ancestry. Approximately 1 in 250–300 Swedish individuals carries homozygous HFE mutations. Most never develop clinical disease if ferritin screening and HFE genotyping happen early. If you have Scandinavian heritage and ferritin > 200 µg/L with low hs-CRP, HFE genotyping is essential — not optional.
Yes — voluntary blood donation is a safe, simple way to shed iron if ferritin is modestly elevated (150–300 µg/L) without confirmed hemochromatosis. Swedish blood banks welcome regular donors and this is a low-friction way to manage iron burden. However, if you carry HFE mutations or have ferritin > 300 µg/L, consult your doctor before donating; you may need formal phlebotomy protocols or HFE-guided management. In hereditary hemochromatosis, phlebotomy is curative and prevents end-organ damage.
Menstruating women lose 10–40 mL of blood per cycle (depending on flow), shedding 5–20 mg of iron monthly. This is why premenopausal women naturally have lower ferritin than men and postmenopausal women. Heavy menstrual bleeding (menorrhagia) accelerates iron depletion and is a common cause of iron deficiency in women of reproductive age. If you have heavy periods and low ferritin, investigate the cause of heavy bleeding (polyps, fibroids, hormonal imbalance) — iron repletion alone is not the full answer.
Dietary iron restriction (avoiding red meat, shellfish, and fortified foods) slows iron accumulation but does not remove accumulated iron — the body has no physiologic iron-excretion pathway. If ferritin is > 200 µg/L with low hs-CRP, phlebotomy (blood donation) is the most effective intervention. Diet is a holding strategy, not a cure. Conversely, if ferritin elevation is driven by inflammation (high hs-CRP), anti-inflammatory lifestyle changes (sleep, training recovery, metabolic flexibility) are primary.
No — supplementation above physiologic need drives unnecessary oxidative stress and is especially risky if you carry HFE mutations or have insulin resistance (both increase hepcidin sensitivity to iron). If ferritin is > 50 µg/L and you have no symptoms of deficiency, supplementation offers no benefit. Your body's tight hepcidin regulation prevents iron toxicity when intake is moderate, but excess supplementation bypasses this control. Eat adequate heme iron (red meat, fish, shellfish) and avoid supplements unless deficient.
